Loading comparison data...
Compare ADALIMUMAB-ADAZ (HYRIMOZ) and INFLIXIMAB-DYYB (INFLECTRA) — clinical data, side effects, and patient experiences.
HYRIMOZ · TNF Inhibitor
How it works
12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...
Approved for
INFLECTRA, Remicade · TNF Inhibitor
How it works
12.1 Mechanism of Action Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit bin...
Approved for
Estimated frequency (%) based on clinical trial data
Based on 8 Reddit discussions
ADALIMUMAB-ADAZ
0%
positive
0 threads
INFLIXIMAB-DYYB
13%
positive
8 threads
% of discussions mentioning each side effect
No community discussions found for ADALIMUMAB-ADAZ yet.
8 Reddit threads analysed for INFLIXIMAB-DYYB
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
56 upvotes
Most discussed side effects in community
I’m a hospital worker so I was able to get the vaccine (Pfizer brand) today. I wanted to share my experience with everyone as I had a lot of fear and doubts about getting it myself. Everything went extremely well, so far I have no side effects at all and it’s been about 4 hours. My arm doesn’t even
I’m bored and have a funny story, so I thought I’d share. I’m in the worst Crohn’s flare up thing of my life, which was brought on by a series of traumatic experiences. Inflectra/Remicade/Infliximab doesn’t work on me anymore apparently and neither do steroids, so my doctor changed me to Entivio re
Hi everyone, I had the idea of putting together a community developed survey for those of us diagnosed with Crohn's disease. The survey could allow us to gain insights into many different aspects of the Crohn's community. I am curious if anyone has some questions they would like to be included, if
Long of the short I was diagnosed with UC in 2020. Took mesalamine until December of 2025. Two flares one in October 2024 (lost 30 lbs) second and ongoing flare July 2025-present. I can’t gain any weight back. I started Inflectra in Feb of 2026 and just had my second dose. I am currently in a flare
I'm starting on Inflectra on Friday, and I'm a bit nervous, wondering: what might I expect? What I can bring to make the experience better? I have Crohn's and perianal disease (with two draining setons from a recent surgery). Planning on bringing some audiobooks, my donut pillow, and some snacks, bu
QUICK BIO: Was first diagnosed with UC in 2015. Was fairly moderate until 2020, when worsening symptoms led me to starting infusions of Inflectra. Was on that steady for nearly three years until my GI took me off of it because my inflammation markers still weren't looking good enough. I was on zero
What are some good resources for pharmacists to learn more about non-oncology infusion medications like IV iron infusions, Inflectra, Entyvio, Remicade, Benylsta, IVIG, IV bisphosphonates…? Any good podcasts? Trying to learn more about the drugs from an outpatient infusion setting but disease state
Source from: [http://bestintheuniverse.net/news/258/title/Sure-Cure-For-Ankylosing-Spondylitis](http://bestintheuniverse.net/news/258/title/Sure-Cure-For-Ankylosing-Spondylitis) **Ankylosing spondylitis** (AS) is a chronic condition. It’s a form of arthritis that causes inflammation in the joints o
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
Both ADALIMUMAB-ADAZ and INFLIXIMAB-DYYB belong to the TNF Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ADALIMUMAB-ADAZ is administered via Subcutaneous, whereas INFLIXIMAB-DYYB uses Intravenous. Route of administration can affect onset of action and patient adherence.
Both medications are approved for inhibiting the progression of structural damage, inhibiting the progression of structural damage. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
ADALIMUMAB-ADAZ carries 4 FDA warnings. INFLIXIMAB-DYYB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.
Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.